Form 4: ZEVRA CEO McFarlane Reports Stock Sales, Option Grants

ZEVRA Therapeutics CEO Neil F. McFarlane reported recent stock sales and new equity grants, including restricted stock units and stock options.

Summary

• Neil F. McFarlane, President and CEO of ZEVRA THERAPEUTICS, INC., reported multiple transactions involving the company's common stock and derivative securities.
• On January 31, 2026, McFarlane acquired 233,334 shares of common stock, which resulted from the vesting and settlement of previously granted restricted stock units.
• On February 2, 2026, McFarlane sold 91,000 shares of common stock at a weighted average price of $9.3783 per share. This transaction was executed pursuant to a Rule 10b5-1(c) plan adopted on March 21, 2025.
• On January 29, 2026, McFarlane was granted 125,000 new restricted stock units (RSUs). These RSUs are scheduled to vest as to one-third on January 29, 2027, with the remaining two-thirds vesting in equal annual installments thereafter, contingent on continued service.
• Also on January 29, 2026, McFarlane received a grant of 250,000 stock options under the Issuer's Amended and Restated 2014 Equity Incentive Plan. These options have an exercise price of $8.86, an expiration date of January 28, 2036, and will vest in four equal annual installments beginning on the first anniversary of the grant date.
• Following these reported transactions, McFarlane directly beneficially owns 364,350 shares of common stock, 125,000 restricted stock units from the new grant, 250,000 stock options, and 233,333 restricted stock units from a prior grant.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing. While the CEO sold shares, it was under a 10b5-1 plan, and new equity grants demonstrate continued long-term incentive alignment, which is generally favorable for investor confidence.

Positives

• Grant of 125,000 new Restricted Stock Units (RSUs) to the CEO, aligning management incentives with long-term shareholder value.
• Grant of 250,000 new stock options with an exercise price of $8.86, providing further incentive for stock price appreciation and long-term performance.

Negatives

• Sale of 91,000 shares of common stock by the CEO at a weighted average price of $9.3783, which reduces direct ownership.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly those involving both sales and new equity grants, are common for executives. Sales often occur for diversification or liquidity, especially when executed under a pre-arranged 10b5-1 plan, which helps mitigate concerns about opportunistic timing. The simultaneous grant of new equity awards indicates continued long-term incentive alignment, a standard practice in the biotechnology and pharmaceutical sectors to retain and motivate key leadership.

Related Party Transactions

• The reported transactions involve the President and CEO of ZEVRA THERAPEUTICS, INC., Neil F. McFarlane, engaging in equity transactions with the company, which are inherently related-party dealings.

Stakeholder Impact

• Shareholders: The sale by the CEO could be perceived negatively, but the execution under a 10b5-1 plan mitigates concerns about opportunistic timing. The new equity grants align the CEO's interests with long-term shareholder value.
• Employees: No direct impact on employees is mentioned, but executive compensation structure can influence morale and perception of leadership and company stability.

Next Steps

• Continued vesting of 125,000 Restricted Stock Units, with the first third vesting on January 29, 2027, and subsequent annual installments.
• Continued vesting of 250,000 Stock Options in four equal annual installments, commencing on the first anniversary of the grant date (January 29, 2027).
• Vesting and settlement of the remaining one-third of previously granted Restricted Stock Units on January 31, 2027.

Key Dates

Recommendation

The filing details routine insider transactions, including both sales under a pre-arranged plan and new equity grants. These actions are typical for executives managing personal finances and receiving compensation, and do not present a strong signal for a 'buy' or 'sell' recommendation based solely on this Form 4. The new grants indicate continued commitment and incentive alignment, while the sale is a planned liquidity event. Therefore, a 'hold' recommendation is appropriate as this filing does not fundamentally alter the investment thesis.

Keywords

ZEVRA Therapeutics, ZVRA, Insider Trading, Form 4, Stock Option, Restricted Stock Unit, CEO, Equity Grant, Stock Sale, 10b5-1 Plan